Kahraman, SedaErul, EnesSeyyar, MustafaGümüşay, ÖzgeBayram, ErtuğrulAksoy, SercanÖzkanlı, Gülhan2024-01-252024-01-252023Kahraman, S., Erul, E., Seyyar, M., Gümüşay, O., Bayram, E., Demirel, B. C., … Nahit Sendur, M. A. (2023). Treatment efficacy of ribociclib or palbociclib plus letrozole in hormone receptor-positive/HER2-negative metastatic breast cancer. Future Oncology, 19(10), 727–736. https://doi.org/10.2217/fon-2022-12871479-66941744-8301https://doi.org/10.2217/fon-2022-1287https://hdl.handle.net/20.500.12428/5423Background: Ribociclib, palbociclib and abemaciclib are currently approved CDK4/6 inhibitors along with aromatase inhibitors as the first-line standard-of-care for patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Methods: The authors report retrospective real-life data for 600 patients with estrogen receptor- and/or progesterone receptor-positive and HER2-negative metastatic breast cancer who were treated with ribociclib and palbociclib in combination with letrozole. Results & conclusion: The results demonstrated that the combination of palbociclib or ribociclib with letrozole has similar progression-free survival and overall survival benefit in real life for the patient group with similar clinical features. Specifically, endocrine sensitivity may be a factor to be considered in the treatment preference.eninfo:eu-repo/semantics/closedAccessCDK 4/6 inhibitorsHER2-negative metastatic breast cancerHR-positiveLetrozoleArticle191072773610.2217/fon-2022-1287Q3WOS:0009916467000012-s2.0-8515973194737133230